Zacks Investment Research upgraded shares of Heron Therapeutics Inc. (NASDAQ:HRTX) from a sell rating to a hold rating in a report published on Tuesday morning.

According to Zacks, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. “

Other analysts have also issued research reports about the company. Leerink Swann reaffirmed a buy rating and set a $33.00 price objective on shares of Heron Therapeutics in a research note on Sunday, October 2nd. Cowen and Company reaffirmed a buy rating on shares of Heron Therapeutics in a research note on Saturday, July 9th. Cantor Fitzgerald reaffirmed a buy rating and set a $41.00 price objective on shares of Heron Therapeutics in a research note on Wednesday, August 3rd. Brean Capital reiterated a buy rating and set a $55.00 target price on shares of Heron Therapeutics in a research report on Saturday, August 13th. Finally, Jefferies Group reiterated a buy rating and set a $46.00 target price on shares of Heron Therapeutics in a research report on Wednesday, July 27th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Heron Therapeutics presently has an average rating of Buy and an average price target of $42.29.

Shares of Heron Therapeutics (NASDAQ:HRTX) opened at 16.29 on Tuesday. Heron Therapeutics has a 52-week low of $15.13 and a 52-week high of $31.32. The firm’s 50 day moving average is $18.38 and its 200 day moving average is $18.91.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Monday, August 8th. The biotechnology company reported ($1.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.96) by $0.21. Equities analysts anticipate that Heron Therapeutics will post ($4.39) EPS for the current fiscal year.

In other Heron Therapeutics news, insider Robert Rosen sold 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 10th. The stock was sold at an average price of $23.30, for a total transaction of $2,330,000.00. Following the completion of the sale, the insider now owns 102,640 shares in the company, valued at approximately $2,391,512. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 20.31% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. raised its stake in shares of Heron Therapeutics by 6.0% in the first quarter. JPMorgan Chase & Co. now owns 348,685 shares of the biotechnology company’s stock worth $6,622,000 after buying an additional 19,737 shares during the period. VHCP Management II LLC purchased a new position in shares of Heron Therapeutics during the first quarter valued at approximately $7,708,000. Jacobs Levy Equity Management Inc. purchased a new position in shares of Heron Therapeutics during the first quarter valued at approximately $734,000. Panagora Asset Management Inc. raised its position in shares of Heron Therapeutics by 90.3% in the first quarter. Panagora Asset Management Inc. now owns 245,392 shares of the biotechnology company’s stock valued at $4,660,000 after buying an additional 116,461 shares during the last quarter. Finally, Cormorant Asset Management LLC raised its position in shares of Heron Therapeutics by 3.8% in the first quarter. Cormorant Asset Management LLC now owns 1,750,000 shares of the biotechnology company’s stock valued at $33,233,000 after buying an additional 64,281 shares during the last quarter.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

5 Day Chart for NASDAQ:HRTX

Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.